Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JUNE 2017. Refer to TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | everolimus (Afinitor®) | ||
| Formulation | tablet | ||
| Reference number | 142 | ||
| Indication | Treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease |
||
| Company | Novartis Pharmaceuticals UK Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Full | ||
| Status | Superseded | ||
| Advice number | 2112 | ||
| NMG meeting date | 12/06/2012 | ||
| AWMSG meeting date | 18/07/2012 | ||
| Ratification by Welsh Government | 07/08/2012 | ||
| Date of issue | 13/08/2012 | ||
| Date of last review | 30/08/2016 | ||
| NICE guidance | |||